Follow-up: BitcoinVersus.Tech reported in July that a Harvard-linked cellular rejuvenation program had entered its first human clinical trial. That story now has its first major clinical checkpoint: Life Biosciences says it will present the first interim human data from the Phase 1 ER-100 trial on October 8 at Eyecelerator @ AAO 2026 in New Orleans.
The October 1 announcement does not disclose the results in advance. It says Chief Scientific Officer Sharon Rosenzweig-Lipson, PhD, will present new interim data from glaucoma patients at 2:10 p.m. CT on October 8. Until those data are public, claims about safety or restored human vision would be premature.
From first human dosing to first human data
BitcoinVersus.Tech’s July report covered the move from animal research into human testing. The Phase 1 study evaluates ER-100 in optic neuropathies including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, or NAION.
ER-100 uses controlled expression of three transcription factors—OCT4, SOX2 and KLF4, collectively OSK—with the goal of resetting patterns of gene expression associated with cellular aging while preserving cell identity. The trial’s primary focus is safety and tolerability, with additional measures examining visual function.
Life Biosciences co-founder and Harvard Medical School genetics professor David Sinclair highlighted the upcoming presentation in an October 1 X post, calling attention to the first-in-human Phase 1 data.
Why the October 8 presentation matters
The significance is not that age reversal in humans has already been demonstrated. It has not. The significance is that a partial epigenetic reprogramming approach has progressed far enough for investigators to begin reporting observations from treated human patients.
That distinction matters because preclinical results do not guarantee human efficacy. WIRED reported when the first participant was dosed that the study was expected to involve roughly 18 adults and was designed first to assess safety and side effects, even as researchers explore whether the approach can improve visual function.
The clinical transition follows the FDA authorization BitcoinVersus.Tech covered earlier in May, when ER-100 was preparing for human testing. The October presentation is therefore the next evidence point in a chain that moved from preclinical restoration experiments to regulatory clearance, dosing and now human observations.
What ER-100 is actually trying to repair
Open-angle glaucoma and NAION damage retinal ganglion cells, neurons that carry visual information from the retina toward the brain. These cells do not naturally regenerate after severe damage, which is why permanent vision loss is such an important endpoint for researchers.
ER-100 is intended to restore more youthful patterns of gene expression in those damaged cells rather than simply lowering an external risk factor. That is a substantially different therapeutic proposition from conventional glaucoma management, but it remains investigational.
The key questions the first data can begin answering
The October 8 presentation should be judged primarily on what Phase 1 trials are built to establish: whether the therapy is tolerable, what adverse events appear, whether the delivery and activation strategy behaves as intended, and whether any exploratory visual-function signals justify continued study.
Even a positive early signal would not establish that human aging has been reversed broadly. ER-100 is being administered locally for specific optic neuropathies, and the study remains small. Longer follow-up, additional patients and controlled evidence would be needed before making wider conclusions.
The underlying field nevertheless overlaps with BitcoinVersus.Tech’s longer-running coverage of genetic technologies, including our discussion of CRISPR-Cas9 and human longevity. CRISPR gene editing and OSK epigenetic restoration are different technologies, but both illustrate how biotechnology is moving from descriptive biology toward interventions intended to alter cellular behavior.
The next follow-up is only days away
This story now has a precise next checkpoint: October 8, 2026. BitcoinVersus.Tech will be able to compare the actual presentation with the claims and expectations surrounding the trial once Life Biosciences releases the first human ER-100 data.
For now, the scientifically important development is straightforward: the first human partial-epigenetic-restoration trial has moved beyond dosing and is preparing to disclose its first clinical observations. What those observations show remains an open question.
BitcoinVersus.Tech
Advertisement
Editor’s Note
We volunteer daily to ensure the credibility of the information on this platform is Verifiably True. If you would like to support to help further secure the integrity of our research initiatives, please donate here: 3C9o19EH5HSiwEPyCTmEKzxhNCbo2X6TTb
BitcoinVersus.tech is not a financial advisor. This media platform reports on financial subjects purely for informational purposes.
Leave a comment